|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L02BB04
|
|
gptkbp:blackBoxWarning
|
none
|
|
gptkbp:brand
|
gptkb:Xtandi
|
|
gptkbp:CASNumber
|
915087-33-1
|
|
gptkbp:chemicalFormula
|
C21H16F4N4O2S
|
|
gptkbp:clinicalTrialPhase
|
Phase III
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developer
|
gptkb:Astellas_Pharma
gptkb:Medivation
|
|
gptkbp:drugClass
|
hormonal antineoplastic agent
antiandrogen
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
capsule
|
|
gptkbp:genericName
|
gptkb:enzalutamide
|
|
gptkbp:halfLife
|
5.8 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Xtandi
|
|
gptkbp:indication
|
metastatic castration-resistant prostate cancer
non-metastatic castration-resistant prostate cancer
|
|
gptkbp:legalStatus
|
prescription only
Rx-only (US)
|
|
gptkbp:marketedIn
|
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
androgen receptor inhibitor
|
|
gptkbp:metabolism
|
hepatic (CYP2C8, CYP3A4)
|
|
gptkbp:molecularWeight
|
464.44 g/mol
|
|
gptkbp:patent
|
gptkb:Pfizer
gptkb:Astellas_Pharma
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
gptkb:D_(Australia)
Contraindicated
|
|
gptkbp:prescribedWith
|
androgen deprivation therapy
|
|
gptkbp:prescriptionRequired
|
https://www.xtandi.com/
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
fatigue
hypertension
seizures
hot flashes
|
|
gptkbp:synonym
|
gptkb:enzalutamide
|
|
gptkbp:usedFor
|
prostate cancer
|
|
gptkbp:bfsParent
|
gptkb:Astellas_Pharma
|
|
gptkbp:bfsLayer
|
5
|